Cargando…
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
BACKGROUND: Anti-CTLA-4 immune checkpoint blockade is associated with immune-related adverse events (irAEs). Grade 3–4 diarrhea/colitis is the most frequent irAE requiring treatment discontinuation. Predicting high-risk diarrhea/colitis patients may facilitate early intervention, limit irAE severity...
Autores principales: | Friedlander, Philip, Wood, Kevin, Wassmann, Karl, Christenfeld, Alan M., Bhardwaj, Nina, Oh, William K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145108/ https://www.ncbi.nlm.nih.gov/pubmed/30227886 http://dx.doi.org/10.1186/s40425-018-0408-9 |
Ejemplares similares
-
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab
por: Friedlander, Philip, et al.
Publicado: (2017) -
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases
por: Page, David B., et al.
Publicado: (2022) -
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
por: He, Mengnan, et al.
Publicado: (2017) -
Tremelimumab
Publicado: (2012) -
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)